Exchange: EURONEXT Industry: Drug Manufacturers General
0.00% €101.40
America/New_York / 8 jun 2023 @ 11:35
FUNDAMENTALS | |
---|---|
MarketCap: | 260 608 mill |
EPS: | 4.82 |
P/E: | 21.04 |
Earnings Date: | Jul 30, 2024 |
SharesOutstanding: | 2 570.10 mill |
Avg Daily Volume: | 0 mill |
RATING 2023-06-20 |
---|
S- |
Strong Buy |
RATINGS | ||
---|---|---|
Rating CashFlow: | Neutral | |
Return On Equity: | Strong Buy | |
Return On Asset: | Strong Buy | |
DE: | Buy | |
P/E: | Strong Buy | |
Price To Book: | Strong Buy |
QUARTER GROWTHS | ||||||
---|---|---|---|---|---|---|
4/22 | 1/23 | 2/23 | 3/23 | 4/23 | 1/24 | |
Revenue | ||||||
Gr.Profit | ||||||
Ebit | ||||||
Asset | ||||||
Debt |
PE RATIO: COMPANY / SECTOR |
---|
1.19x |
Company: PE 21.04 | sector: PE 17.68 |
PE RATIO: COMPANY / INDUSTRY |
---|
1.17x |
Company: PE 21.04 | industry: PE 17.94 |
DISCOUNTED CASH FLOW VALUE |
---|
N/A |
N/A |
Expected Trading Range (DAY) |
---|
€ 99.09 - 103.71 ( +/- 2.28%) |
ATR Model: 14 days |
Indicator Signals | |
---|---|
RSI 21 | |
SMA | |
Trend | |
Trend 2 | |
Trend 3 | |
MACD |
Volume Signals | |
---|---|
Price | €101.40 (0.00% ) |
Volume | 0.0003 mill |
Avg. Vol. | 0 mill |
% of Avg. Vol | 0 % |
Signal 1: | |
Signal 2: |
0 Signals | Accuracy: 0.00% | Accuracy Buy: 0.00% | Accuracy Sell: 0.00%
Avg return buy: 0.00 % | Avg return sell: 0.00 %
$1 invested is now $1.00 or 0.00% since Coming Soon
Date | Signal | @ | Closed | % |
---|
Merck & Co., Inc. operates as a healthcare company worldwide. It operates through two segments, Pharmaceutical and Animal Health. The Pharmaceutical segment offers human health pharmaceutical products in the areas of oncology, hospital acute care, immunology, neuroscience, virology, cardiovascular, and diabetes, as well as vaccine products, such as preventive pediatric, adolescent, and adult vaccines. The Animal Health segment discovers, develops, manufactures, and markets veterinary pharmaceuticals, vaccines, and health management solutions and services, as well as digitally connected identification, traceability, and monitoring products. It serves drug wholesalers and retailers, hospitals, and government agencies; managed health care providers, such as health maintenance organizations, pharmacy benefit managers, and other institutions; and physicians and physician distributors, veterinarians, and animal producers. The company has collaborations with AstraZeneca PLC; Bayer AG; Eisai Co., Ltd.; Ridgeback Biotherapeutics; and Gilead Sciences, Inc. to jointly develop and commercialize long-acting treatments in HIV. Merck & Co., Inc. was founded in 1891 and is headquartered in Kenilworth, New Jersey.